Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 827-834

  Hassuneh, Mona R ^a   Nagarkatti, Mitzi ^b   Nagarkatti, Prakash S ^b  

^a UNIVERSITY OF JORDAN   (Jordan)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

IL 10 gene expression; Lymphoma; Tumorigenicity

Indexed keywords

INTERLEUKIN 10; PROTEIN RET;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; T CELL LYMPHOMA;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOXYCYCLINE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; INTERLEUKIN-10; INTERLEUKIN-4; LYMPHOMA, T-CELL; MICE;

EID: 84879546865     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.726721     Document Type: Article

References (52)

1. Vieira P, de Waal-Malefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991; 88: 1172-1176.
2. Fiorentino D F, Bond M W, Mosmann T R. T wo types of mouse helper T cell. IV. Th 2 clones secrete a factor that inhibits cytokine production by Th 1 clones. J Exp Med 1989; 170: 2081-2095.
3. Moore KW, de Waal Malefyt R, Coff man RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
4. deWaal Malefyt R, Haanen J, Spits H, et al. IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med 1991; 174: 915-924.
5. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by T H 1 cells. J Immunol 1991; 146: 3444-3451.
6. Ding L, Shevach E M. I L-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148: 3133-3139.
7. Hsu DH, Moore KW, Spits H. Diff erential Effects of interleukin-4 and -10 on interleukin-2-induced interferon-g synthesis and lymphokine-activated killer activity. Int Immunol 1992; 4: 563-569.
8. Oswald I P, Gazzinelli R T, Sher A, et al. IL-10 synergizes with IL-4 and TGF-beta to inhibit macrophage cytotoxic activity. J Immunol 1992; 148: 3578-3582.
9. Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, Tlymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148: 808-814.
10. Murphy EE, Terres G, Macatonia SE, et al. B7 and interleukin-12 cooperate for proliferation and IFN © production by mouse Th 1 clones that are unresponsive to B7 costimulation. J Exp Med 1994; 80: 223-231.
11. D' Andrea A, Aste AM, Valiante NM, et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-1048.
12. Gruber MF, Williams C C, Gerrard T L. M acrophage-colonystimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 beta and inhibited by IL-4 and IL-10. J Immunol 1994; 152: 1354-1361.
13. Kopydlowski KM, Salkowski CA, Cody MJ, et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 1999; 163: 1537-1544.
14. Hart PH, Hunt EK, Bonder CS, et al. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 1996; 157: 3672-3680.
15. Gray D, Gray M. W hat are regulatory B cells? E ur J Immunol 2010; 40: 2677-2679.
16. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50.
17. Kü hn R, Lö hler J, Rennick D, et al. Interleukin-10-defi cient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
18. Berg DJ, Davidson N, Kü hn R, et al. Enterocolitis and colon cancer in interleukin-10-defi cient mice are associated with aberrant cytokine production and CD4 + T H 1-like responses. J Clin Invest 1996; 98: 1010-1020.
19. Rennick DM, Fort MM. Lessons from genetically engineered animal models XII. IL-10-defi cient (IL-10-/-) mice and intestinal infl ammation. Am J Physiol Gastrointest Liver Physiol 2000; 278: 829-833.
20. Singh B, Read S, Asseman C, et al. Control of intestinal infl ammation by regulatory T cells. Immunol Rev 2001; 182: 190-200.
21. Eruslanov E, Kaliberov S, Daurkin I, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor infi ltrated CD11b myeloid cells: A mechanism for immune evasion in cancer. J Immunol 2009; 182: 7548-7557.
22. Ikeguchi M, Hatada T, Yamamoto M, et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009; 12: 95-100.
23. Chau G Y, W u C W, Lui W Y, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231: 552-528.
24. Salazar-Onfray F, Ló pez MN, Mendoza-Naranjo A. Paradoxical Effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182.
25. Sharma S, Stolina M, Lin Y, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163: 5020-5028.
26. Qin Z, Noff z G, Mohaupt M, et al. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocytemacrophage colony-stimulating factor gene-modifi ed tumor cells. J Immunol 1997; 159: 770-776.
27. Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999; 59: 911-917.
28. Silini G, Maruyama Y. Studies of the LSA ascites lymphoma of C57BL mice. I. Transplantation characteristics and radiosensitivity of cells during serial passage. J. Natl Cancer Inst 1965; 35: 841-849.
29. Nagarkatti M, Toney DM, Nagarkatti PS. Immunomodulation by various nitrosoureas and its Effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res 1989; 49: 6587-6592.
30. Nagarkatti M, Clary SR, Nagarkatti PS. Characterization of tumorinfi ltrating CD4 + T cells as Th 1 cells based on lymphokine secretion and functional properties. J Immunol 1990; 144: 4898-4905.
31. Weiss B, Davidkova G, Zhou L-W. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 1999; 55: 334-358.
32. Nagarkatti M, Hassuneh M, Seth A, et al. Constitutive activation of the interleukin-2 gene in the induction of spontaneous in vitro transformation and tumorigenicity of T cells. Proc Natl Acad Sci USA 1994; 91: 7638-7642.
33. de Waal Malefyt R, Yssel H, de Vries JE. Direct Effects of IL-10 on subsets of human CD4 + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754-4765.
34. Hassuneh MR, Nagarkatti PS, Nagarkatti M. Evidence for the participation of IL-2 and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin. Blood 1997; 89: 610-620.
35. Hammond-McKibben DM, Seth A, Nagarkatti PS, et al. Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone:role of interleukin-2, cycling pattern of lytic activity and adhesion molecules. Int J Cancer 1995; 16;60: 828-836.
36. Nagarkatti M, Kaplan AM. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol 1985; 135: 1510-1517.
37. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 2371-2376.
38. Salazar-Onfray F, Petersson M, Franksson L, et al. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 1995; 154: 6291-6298.
39. Rohrer JW, Coggin JH. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995; 155: 5719-5727.
40. Wang L, Goillot E, Tepper RI. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell Immunol 1994; 159: 152-169.
41. Trotta R, Col JD, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008; 181: 3784-3792.
42. Gays F, Martin K, Kenefeck R, et al. Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J Immunol 2005; 175: 2938-2947.
43. Llanes-Fern á ndez L, Arango-Prado MC, Alcocer-Gonz á lez JM, et al. Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients. J Cancer Res Clin Oncol 2009; 135: 255-264.
44. Inagaki A, Ishida T, Ishii T, et al. Clinical significance of serum Th1-, Th2-and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: High interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006; 118: 3054-3061.
45. Tsimberidou AM, Estey E, Wen S, et al. The prognostic signifi cance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113: 1605-1613.
46. Nemunaitis J, Fong T, Shabe P, et al. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001; 19: 239-247.
47. Ohara M, Yamaguchi Y, Matsuura K, et al. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother 2009; 58: 441-447.
48. Dummer W, Bastian BC, Ernst N, et al. Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 29;66: 607-610.
49. Giovarelli M, Musiani P, Modesti A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995; 155: 3112-3123.
50. Richter G, Kr ü ger-Krasagakes S, Hein G, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infi ltration. Cancer Res 1993; 15;53: 4134-4137
51. Zeytun A, Hassuneh M, Nagarkatti M, et al. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two way street. Blood 1997; 90: 1952-1959.
52. Zeytun A, Nagarkatti M, Nagarkatti PS. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas (+) organs. Blood 2000; 95: 2111-2117.